BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
BioCryst Pharmicals更新了与Torii Pharmacetica在日本的ORLADEYO协议;BioCryst Japan K.K. 负责所有商业促销活动,Torii 将负责遗传性血管性水肿疾病宣传活动
BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
BioCryst Pharmicals更新了与Torii Pharmacetica在日本的ORLADEYO协议;BioCryst Japan K.K. 负责所有商业促销活动,Torii 将负责遗传性血管性水肿疾病宣传活动